Hybio Pharmaceutical (300199)

10.25 +0.04 (+0.39%)
Close CNY Disclaimer

Hybio Pharmaceutical Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
975
Equity Type
ORD
Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.
Contact Information
Address
Huangpi District Wuhan, China
Phone
86 75 5265 88037
Fax
-
Top Executives
Name
Age
Since
Title
Lian Zhong 64 0000 Independent Director
Yu Pinxiang 51 2020 Executive VP & Director
Shaobin Zeng 47 2020 Non-Independent Director
Di Yang 39 2021 VP, Secretary & Director
Shaogui Zeng 56 2021 Chairman
Lu Yang 42 2021 Member of Non-Employee Supervisory Board
Yao Li 47 2021 Independent Director
Lin Liang 47 0000 Supervisor
Shaoqiang Zeng 53 2021 Vice Chairman
Yangming Tang 46 2021 VP & Director
Wenyan Hu 54 2021 Independent Director
Qingyang Li 48 2021 Chairman of Supervisory Board
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles